Clinical Application of Induced Pluripotent Stem Cells in Muscular Dystrophy
Using patient-derived induced pluripotent stem (iPS) cells, different pathogenesis of neuromuscular diseases have been analyzed, leading toward significant progress in screening for treatment.
At the recent 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 19-22, in Dallas, Texas, Rita Perlingeiro, PhD, recently presented a talk on the potential of using iPS cells in the treatment of muscular dystrophy. The rest of the session focused on the use of patient-specific iPS cells to model neuromuscular diseases, with the goal of understanding disease pathogenesis and treatment development. Also, the session emphasized the expansion of bioengineering approaches for skeletal muscle modeling.
“We have demonstrated in many studies that the (induced pluripotent stem [iPS]) cells must be transplanting animal models of muscular dystrophy. We are able to generate healthy muscle that's functional, and the cells are able also to see the stem cell, which is very important for long term regeneration.”Dr Perlingeiro said.
ارسال به دوستان